$13.09
0.352.75%
At close: -
$12.93
-0.16-1.22%
After Hours: 7:19 PM EDT
Comments
Loading...
Keros Therapeutics Insider Trading Activity | NASDAQ:KROS | Benzinga
Track the latest Keros Therapeutics insider trading activity. Stay informed on recent buys, sells, and market impact for Keros Therapeutics stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Keros Therapeutics Inc Insiders Doing?
At Keros Therapeutics Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have report no sales in the last 30 days, meanwhile, insiders have reported buying a total of 934.26K shares for a total value of $9.46M.
Notable Recent Insider Buys and Sales
- On April 11, 2025, ADAR Capital Management LLC, ADAR Partners LP, ADAR Capital Management GP LLC, Daniel Schneeberger, the company's 10% OWNER purchased 934.26K shares for $10.13 each.
Ownership Statistics for Keros Therapeutics Inc
Shares Outstanding
40.562M
Insider Shares Owned
520.385K
Insider Percentage Owned
1.28%
Institutional Shares Held
11.038M
Institutional Percentage Held
27.2%
| Apr 11, 2025 | ADAR Capital Management LLCADAR Partners LPADAR Capital Management GP LLCDaniel Schneeberger | 10% OWNER | 934.26K | $10.13 | $9.46M | BUY | 25.16% | 4.65M | Apr 09 | View |
| Aug 15, 2024 | Carl L Gordon | DIRECTOR | -250.00K | $44.01 | -$11.00M | SELL | -67.65% | 119.52K | Aug 13 | View |
| Aug 15, 2024 | ORBIMED ADVISORS LLCOrbiMed Capital GP VII LLCOrbiMed Genesis GP LLC | DIRECTOR | -250.00K | $44.01 | -$11.00M | SELL | -67.65% | 119.52K | Aug 13 | View |
| Jan 08, 2024 | Keith Regnante | CHIEF FINANCIAL OFFICER | 0.00 | $30.64 | -$1.17M | SELL-OPTIONS | 0.00% | 0.00 | Nov 04 | View |
| Jun 12, 2023 | Keith Regnante | CHIEF FINANCIAL OFFICER | 0.00 | $31.30 | -$1.22M | SELL-OPTIONS | 0.00% | 0.00 | Jun 08 - Jun 09 | View |
| Jan 20, 2023 | Julius Knowles | DIRECTOR | 1.19K | $20.98 | $24.99K | BUY | 0.51% | 233.92K | Apr 13 | View |
| Jul 19, 2022 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $15.15 | -$1.37M | SELL-OPTIONS | 0.00% | 95.10K | Jul 15 | View |
| Jul 15, 2022 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $15.15 | -$56.91K | SELL-OPTIONS | 0.00% | 95.10K | Jul 13 | View |
| May 13, 2022 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $21.10 | -$220.46K | SELL-OPTIONS | 0.00% | 85.70K | May 11 | View |
| Apr 13, 2022 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $31.54 | -$331.11K | SELL-OPTIONS | 0.00% | 85.70K | Apr 11 | View |
| Apr 08, 2022 | Christopher Rovaldi | CHIEF OPERATING OFFICER | 0.00 | $40.50 | -$84.67K | SELL-OPTIONS | 0.00% | 0.00 | Apr 06 | View |
| Apr 06, 2022 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $30.15 | -$474.62K | SELL-OPTIONS | 0.00% | 85.70K | Apr 04 | View |
| Apr 05, 2022 | Christopher Rovaldi | CHIEF OPERATING OFFICER | 0.00 | $36.75 | -$35.85K | SELL-OPTIONS | 0.00% | 0.00 | Apr 01 | View |
| Mar 15, 2022 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $26.84 | -$140.65K | SELL-OPTIONS | 0.00% | 85.70K | Mar 11 | View |
| Feb 15, 2022 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $26.18 | -$137.17K | SELL-OPTIONS | 0.00% | 85.70K | Feb 11 | View |
| Jan 13, 2022 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $27.03 | -$141.65K | SELL-OPTIONS | 0.00% | 85.70K | Jan 11 | View |
| Jan 07, 2022 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $30.15 | -$158.21K | SELL-OPTIONS | 0.00% | 85.70K | Jan 05 | View |
| Jan 05, 2022 | Julius Knowles | DIRECTOR | -47.65K | $57.84 | -$2.76M | SELL | -17.00% | 232.73K | Jan 03 - Jan 05 | View |
| Dec 15, 2021 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $25.35 | -$132.76K | SELL-OPTIONS | 0.00% | 85.70K | Dec 13 - Dec 15 | View |
| Dec 03, 2021 | Julius Knowles | DIRECTOR | -47.65K | $54.09 | -$2.58M | SELL | -15.93% | 251.54K | Dec 01 - Dec 02 | View |
| Nov 12, 2021 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $30.10 | -$1.26M | SELL-OPTIONS | 0.00% | 85.70K | Nov 10 - Nov 11 | View |
| Nov 05, 2021 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $25.15 | -$526.82K | SELL-OPTIONS | 0.00% | 85.70K | Nov 04 | View |
| Nov 03, 2021 | Julius Knowles | DIRECTOR | -47.65K | $42.12 | -$2.01M | SELL | -14.98% | 270.35K | Nov 01 - Nov 03 | View |
| Oct 21, 2021 | Julius Knowles | DIRECTOR | -8.60K | $38.20 | -$328.44K | SELL | -2.89% | 289.16K | Oct 19 - Oct 20 | View |
| Oct 18, 2021 | Julius Knowles | DIRECTOR | -26.37K | $38.56 | -$1.02M | SELL | -8.27% | 292.55K | Oct 14 - Oct 18 | View |
| Oct 05, 2021 | Julius Knowles | DIRECTOR | -12.69K | $40.10 | -$508.75K | SELL | -4.02% | 302.96K | Oct 01 - Oct 05 | View |
| Sep 29, 2021 | Julius Knowles | DIRECTOR | -95.30K | $41.17 | -$3.92M | SELL | -23.63% | 307.97K | Sep 27 | View |
| Jul 06, 2021 | Julius Knowles | DIRECTOR | -47.65K | $41.31 | -$1.97M | SELL | -12.12% | 345.58K | Jul 01 - Jul 02 | View |
| Jun 15, 2021 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $25.64 | -$134.29K | SELL-OPTIONS | 0.00% | 77.91K | Jun 11 | View |
| Jun 15, 2021 | Claudia Ordonez | CHIEF MEDICAL OFFICER | 0.00 | $25.74 | -$50.51K | SELL-OPTIONS | 0.00% | 0.00 | Jun 11 | View |
| Jun 08, 2021 | Julius Knowles | DIRECTOR | -19.41K | $49.07 | -$952.61K | SELL | -5.06% | 364.39K | Jun 04 - Jun 07 | View |
| Jun 03, 2021 | Julius Knowles | DIRECTOR | -28.24K | $49.71 | -$1.40M | SELL | -7.05% | 372.06K | Jun 01 - Jun 03 | View |
| May 13, 2021 | Claudia Ordonez | CHIEF MEDICAL OFFICER | 0.00 | $25.31 | -$49.67K | SELL-OPTIONS | 0.00% | 0.00 | May 11 | View |
| May 13, 2021 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 6.72K | $25.09 | -$130.87K | SELL-OPTIONS | 9.44% | 77.91K | May 11 - May 13 | View |
| May 05, 2021 | Julius Knowles | DIRECTOR | -47.65K | $57.27 | -$2.73M | SELL | -11.06% | 383.20K | May 03 - May 04 | View |
| Apr 14, 2021 | Claudia Ordonez | CHIEF MEDICAL OFFICER | 0.00 | $30.20 | -$59.45K | SELL-OPTIONS | 0.00% | 0.00 | Apr 12 | View |
| Apr 14, 2021 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $30.15 | -$316.44K | SELL-OPTIONS | 0.00% | 71.19K | Apr 12 | View |
| Apr 08, 2021 | Julius Knowles | DIRECTOR | -9.30K | $58.81 | -$546.84K | SELL | -2.26% | 402.01K | Apr 06 | View |
| Apr 05, 2021 | Julius Knowles | DIRECTOR | -38.35K | $59.72 | -$2.29M | SELL | -8.64% | 405.69K | Apr 01 - Apr 05 | View |
| Mar 15, 2021 | Claudia Ordonez | CHIEF MEDICAL OFFICER | 0.00 | $32.52 | -$64.08K | SELL-OPTIONS | 0.00% | 0.00 | Mar 11 | View |
| Mar 15, 2021 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $32.39 | -$340.16K | SELL-OPTIONS | 0.00% | 61.19K | Mar 11 | View |
| Mar 05, 2021 | Julius Knowles | DIRECTOR | -23.96K | $56.45 | -$1.35M | SELL | -5.39% | 420.82K | Mar 03 - Mar 04 | View |
| Mar 03, 2021 | Julius Knowles | DIRECTOR | -23.69K | $61.13 | -$1.45M | SELL | -5.22% | 430.28K | Mar 01 - Mar 02 | View |
| Feb 18, 2021 | Julius Knowles | DIRECTOR | -28.62K | $60.87 | -$1.74M | SELL | -6.11% | 439.63K | Feb 16 - Feb 18 | View |
| Feb 16, 2021 | Julius Knowles | DIRECTOR | -19.03K | $63.53 | -$1.21M | SELL | -4.05% | 450.93K | Feb 11 - Feb 12 | View |
| Feb 16, 2021 | Claudia Ordonez | CHIEF MEDICAL OFFICER | 0.00 | $32.66 | -$64.36K | SELL-OPTIONS | 0.00% | 0.00 | Feb 11 | View |
| Feb 16, 2021 | Jennifer Lachey | CHIEF SCIENTIFIC OFFICER | 0.00 | $32.60 | -$342.43K | SELL-OPTIONS | 0.00% | 27.99K | Feb 11 | View |
| Nov 19, 2020 | Ran NussbaumPontifax Israel IV LPPontifax Cayman IV LPPontifax China IV LPPontifax Late Stage Fund LPPontifax Late Stage GP Ltd | — | 60.00K | $50.00 | $3.00M | PURCHASE | 62.98% | 155.26K | Nov 17 | View |
| Nov 19, 2020 | Tomer KarivPontifax Israel IV LPPontifax Cayman IV LPPontifax China IV LPPontifax Late Stage Fund LPPontifax Late Stage GP Ltd | — | 60.00K | $50.00 | $3.00M | PURCHASE | 62.98% | 155.26K | Nov 17 | View |
| Nov 19, 2020 | Pontifax Management GP LtdPontifax Israel IV LPPontifax Cayman IV LPPontifax China IV LPPontifax Late Stage Fund LPPontifax Late Stage GP Ltd | — | 60.00K | $50.00 | $3.00M | PURCHASE | 62.98% | 155.26K | Nov 17 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.